去年协议期内谈判药品医保基金支出超过1000亿元

Core Insights - The National Healthcare Security Administration (NHSA) announced that the medical insurance fund expenditure for negotiated drugs will exceed 100 billion yuan during the 2024 agreement period [1] - The number of approved innovative Class 1 drugs in China has significantly increased, reaching 48 in 2024, which is more than five times the number in 2018; nearly 40 have been approved in the first half of this year, indicating a surge in approvals [1] - The "Several Measures to Support the High-Quality Development of Innovative Drugs" outlines 16 initiatives across five areas to enhance support for innovative drug research and development, inclusion in medical insurance, clinical application, payment capabilities, and organizational guarantees [1] Industry Developments - The NHSA emphasizes the need to support true innovation and differentiated innovation in the biopharmaceutical industry to avoid excessive competition and homogenization of products [1] - There is a focus on providing necessary medical insurance data services to support innovative drug research while ensuring data security and compliance [1] Medical Insurance Access - The NHSA is negotiating with innovative drug companies to establish medical insurance payment standards, creating a multi-dimensional value assessment system centered on patient health benefits [2] - For cases involving the reasonable use of innovative drugs within the medical insurance directory, medical institutions are supported in independently reporting special cases when standard disease-based payments are not suitable [2] - Innovative drugs listed in commercial health insurance directories will not be included in the basic medical insurance self-payment rate indicators, allowing for more flexible payment arrangements [2]